Cleveland, OH Clinical Trials Report — April 2026

For Cleveland residents considering participation in clinical research, April 2026 presents a crucial window for those looking to join studies before enrollment concludes. Across the city, 98 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on neurological conditions, kidney health, and various cancers are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Rotator cuff tears (2 trials)
• Parkinson's disease (2 trials)
• Glioblastoma multiforme (2 trials)
• Recurrent endometrial carcinoma (2 trials)
• Stroke (2 trials)
• Acute kidney injury (2 trials)
• Deep venous thrombosis (2 trials)

Other conditions with trials closing soon include advanced non-small cell lung cancer (NSCLC) and anal cancer, each with 1 trial.

New Opportunities in Cleveland Research

This month, Cleveland saw the opening of 9 new clinical trials, a decrease from the 11 trials that launched in March 2026. Despite this slight dip in new openings, the city continues to be a vital hub for medical research, with a total of 1,223 clinical trials currently recruiting across 335 research facilities.

April brings several notable new trials to Cleveland, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma.
• Case Comprehensive Cancer Center is sponsoring NCT07524634, "Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis." This Phase 2 research study is for people newly diagnosed with AL (light chain) amyloidosis who have not yet received any treatment for this condition. The trial aims for 64 participants to evaluate whether elranatamab, an immunotherapy drug, can produce deep remissions and organ recovery.
• Anny Reyes is leading NCT07509190, "Bridging the Gap: Educating Patients on Social Determinants of Health to Improve Epilepsy Surgery Access and Outcomes." This study, aiming for 310 participants, seeks to identify needs and barriers to accessing epilepsy surgery and to pilot an educational program regarding social determinants of health and their influence on surgical rates and epilepsy outcomes.

New trials this month are exploring a range of conditions, including amyloid light-chain amyloidosis, various cancers (prostate cancer, malignant peripheral nerve sheath tumors), Down syndrome, epilepsy, Parkinson disease, and studies focused on family caregivers and intellectual disability. Drug trials account for the majority of new studies, with 5 new drug trials, followed by 2 behavioral trials, 2 other types of studies, 1 device trial, and 1 procedure trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute. 2 of the 9 new trials launched this month are actively seeking healthy volunteers. Across Cleveland, a total of 89 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Cleveland's Leading Research Facilities

Cleveland is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Cleveland Clinic (342 trials)
• Cleveland Clinic Foundation (153 trials)
• University Hospitals Cleveland Medical Center (135 trials)
• Case Western Reserve University (79 trials)
• MetroHealth Medical Center (39 trials)
• Research Site (32 trials)
• The Cleveland Clinic Foundation (27 trials)
• Rainbow Babies and Childrens Hospital (26 trials)
• Louis Stokes VA Medical Center, Cleveland, OH (21 trials)
• Cleveland Clinic Main Campus (19 trials)
• Cleveland Clinic Cancer Center/Fairview Hospital (17 trials)
• University Hospitals (13 trials)

The Cleveland Clinic system, including its main campus, foundation, and specialized centers, clearly leads the city in the volume of clinical research, offering a broad spectrum of studies. University Hospitals Cleveland Medical Center and Case Western Reserve University also stand out as major contributors to the local research landscape.

Broadening Your Search: Nearby Options in Ohio

While Cleveland offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Ohio. Cities with active trials include Cincinnati (8 trials), Columbus (7 trials), Akron (2 trials), Youngstown (2 trials), Canal Winchester (1 trial), Canfield (1 trial), Canton (1 trial), and Bay Village (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 9 new trials launched this month, 8 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials are specifically designed for children, and 1 new trial is male-only. Academic institutions, including Case Comprehensive Cancer Center, Case Western Reserve University, and University Hospitals Cleveland Medical Center, are significant sponsors of new research, alongside industry partners like Incyte Corporation.

As we move into the spring, the focus will remain on the ongoing enrollment in these significant trials and the continued exploration of new therapeutic strategies, with Cleveland's robust research community at the forefront of medical innovation.